1,4-顺-1-(1-环辛烯-1-基甲基)-4-[[((2,7-二氯-9H-黄嘌呤-9-基)羰基]氨基]-1-乙基碘化碘鎓

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 1,4-顺-1-(1-环辛烯-1-基甲基)-4-[[((2,7-二氯-9H-黄嘌呤-9-基)羰基]氨基]-1-乙基碘化碘鎓
• 中文别名: 1,4-反-1-(1-环辛烯-1-基甲基)-4-[[((2,7-二氯-9H-黄嘌呤-9-基)羰基]氨基]-1-乙基碘化碘鎓
• 英文名称: 1,4-trans-1-(1-Cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9H-xanthen-9-YL)carbonyl]amino]-1-ethylpiperidinium iodide
• 英文别名: 2,7-dichloro-N-[1-[[(1E)-cycloocten-1-yl]methyl]-1-ethylpiperidin-1-ium-4-yl]-9H-xanthene-9-carboximidate;hydroiodide
• 化学式: C30H37Cl2IN2O2
• 分子量: 655.4
• InChiKey: FOAFBMYSXIGAOX-LQGGPMKRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.63
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0916668A1

  公开（公告）日：1999-05-19

  The present invention relates to a compound of the general formula: wherein each of R1 and R2 which may be the same or different, is e.g. a hydrogen atom, a halogen atom or a lower alkyl group, X is an oxygen atom, a sulfur atom or CH, Y is CH or a nitrogen atom, and A is e.g. a 1-substituted-4-piperidinyl group, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable anion-exchange product thereof or a hydrate thereof. The compounds of the present invention have chemokine receptor antagonism, and thus they are useful as treating agents for various diseases relating to chemokine, such as acute inflammatory diseases, chronic inflammatory diseases, acquired immune deficiency syndrome, cancer, ischemic reflow disorder and/or arteriosclerosis.

  本发明涉及通式如下的化合物： 其中R1和R2可以相同或不同，每个R1和R2例如是氢原子、卤素原子或低级烷基，X是氧原子、硫原子或CH，Y是CH或氮原子，A例如是1-取代-4-哌啶基、其药学上可接受的盐、其药学上可接受的阴离子交换产物或其水合物。 本发明的化合物具有趋化因子受体拮抗作用，因此可作为治疗与趋化因子有关的各种疾病的药物，如急性炎症性疾病、慢性炎症性疾病、获得性免疫缺陷综合征、癌症、缺血性回流障碍和/或动脉硬化。
• Peptide inhibition of CCR3-mediated diseases or conditions
  申请人：The Board of Trustees of the University of Illinois

  公开号：US10363286B2

  公开（公告）日：2019-07-30

  A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

  本文提供了一种C-C趋化因子受体3（CCR3）多肽类似物，它通过与配体结合并抑制配体介导的信号传导和趋化作用，同时促进CCR3的内化和降解，从而表现出偏向拮抗作用，还提供了一种使用该多肽类似物治疗、预防或改善嗜酸性粒细胞或CCR3介导的疾病或病症的一种或多种症状的方法。
• Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US10626399B2

  公开（公告）日：2020-04-21

  Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

  本文提供了治疗成年哺乳动物衰老相关损伤的方法。这些方法的各个方面包括调节哺乳动物体内的 CCR3，例如，通过调节 eotaxin-1/CCR3 相互作用，足以治疗哺乳动物的衰老相关损伤。本发明方法可治疗多种衰老相关损伤，其中包括认知损伤。
• Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)
  申请人：THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：US11236340B2

  公开（公告）日：2022-02-01

  Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

  本文提供了治疗成年哺乳动物衰老相关损伤的方法。这些方法的各个方面包括调节哺乳动物体内的 CCR3，例如，通过调节 eotaxin-1/CCR3 相互作用，足以治疗哺乳动物的衰老相关损伤。本发明方法可治疗多种衰老相关损伤，其中包括认知损伤。
• NEW LEUKOCYTE INFILTRATE MARKERS FOR ROSACEA AND USES THEREOF
  申请人：Galderma Research & Development

  公开号：EP2771484A1

  公开（公告）日：2014-09-03